Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
37 hedge funds and large institutions have $345M invested in Paratek Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 13 closing their positions.
2,382% more capital invested
Capital invested by funds: $13.9M → $345M (+$331M)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
3% more funds holding
Funds holding: 36 → 37 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$41.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.4M |
| 3 |
A
Abingworth
London,
United Kingdom
|
+$31.1M |
| 4 |
AC
Aisling Capital
New York
|
+$16.3M |
| 5 |
BC
Broadfin Capital
New York
|
+$6.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$304K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$262K |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$202K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$136K |
| 5 |
Jane Street
New York
|
-$126K |
PRTK Hedge Fund Activity: Q4 2014 in Review
37 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2014, worth a combined $345M — up 2,382% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PRTK positions and 13 closed out — a net gain of 2 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Baupost Group, opening a new position worth an estimated $41.4M. The largest seller was BVF Inc, exiting entirely with an estimated $304K sold.
- 37 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2014, up from 36 in Q3 2014.
- Funds reported $345M of Paratek Pharmaceuticals, Inc. stock for Q4 2014, up 2,382% quarter-over-quarter.
- 15 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2014 and 13 closed out, a net change of +2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2014 was Baupost Group, an estimated $41.4M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2014 was BVF Inc, an estimated $304K sold.
Based on aggregated 13F filings for Q4 2014.